Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

Despite positive efficacy data highlighted at AAN 2024, Axsome Therapeutic’s ASX-07 will struggle to make significant impact in acute migraine market, says GlobalData

Following a poster presentation at the American Academy of Neurology (AAN) 2024 annual meeting of new pooled data from two Phase III trials, MOMENTUM (NCT0389600) and INTRCEPT (NCT04163185), evaluating Axsome Therapeutics’s AXS-07 (MoSEIC™ meloxicam and rizatriptan) as a novel acute combination treatment for migraine; Philippa Salter, Senior Neurology Analyst at GlobalData, a leading data and […]
Read more

AbbVie and NeuroDerm race to US launch of levodopa infusions intensifies with additional benefits highlighted at AAN 2024, says GlobalData

Innovation in drug formulations and delivery systems is one of the most rapidly changing areas in Parkinson’s disease (PD) treatment and is primarily driven by the levodopa market. At the American Academy of Neurology (AAN) 2024 Annual Meeting, data on NeuroDerm’s ND0612 (levodopa/carbidopa, LD/CD) and AbbVie’s Produodopa/Vyalev (foslevodopa/foscarbidopa) were showcased for the treatment of PD […]
Read more

Eli Lilly’s double impact: Mounjaro and Donanemab set to outshine market rivals, says GlobalData

Eli Lilly and Co is on the brink of reshaping the pharmaceutical landscape with its groundbreaking treatments, Mounjaro (tirzepatide) for obesity and the highly anticipated donanemab for early symptomatic Alzheimer’s disease. Both drugs are poised to exceed market expectations and challenge existing industry leaders, marking significant milestones in Eli Lilly’s journey toward market dominance, according […]
Read more

MASH innovator drug partnerships surge over $2.5 billion in 2024YTD, reveals GlobalData

Biopharmaceutical companies are regaining interest in metabolic dysfunction-associated steatohepatitis (MASH) innovator drug development. MASH innovator drugs witnessed over $2.5 billion increase in the total value of partnership deals from 2020 to 2024 year-to-date (YTD), with more than $2 billion forged in Q1 2024 alone, reveals GlobalData, a leading data and analytics company. MASH, previously known […]
Read more

Physicians lack consensus on patient choice between branded and generic drugs, finds GlobalData

Generic drugs present a notable absence of consensus among physicians within the realm of healthcare regarding patients’ choice between branded and generic alternatives. This lack of a clear stance among healthcare providers prompts an in-depth investigation into the myriad factors shaping their perspectives, including efficacy, patient preferences, and cost considerations. Understanding these dynamics is pivotal […]
Read more

Arrowhead Pharmaceuticals plozarsiran holds potential to treat dyslipidemia, says GlobalData

Arrowhead Pharmaceuticals has recently unveiled final data from its Phase II SHASTA-2 clinical trial for plozasiran, previously recognized as ARO-APOC3. The data indicates a substantial reduction in Apolipoprotein C-III (APOC3) and triglycerides by as much as 86% and 90%, respectively. Should it secure approval, plozasiran holds potential to effectively address critical unmet needs in dyslipidemia […]
Read more

US to see surge in new obesity drug launches in next five years, says GlobalData

Over the past two decades, there has been a marked increase in obesity rates among US adults, with projections indicating a continuing upward trend. Two blockbuster drug launches within the last few years—Novo Nordisk’s Wegovy (semaglutide) and Eli Lilly’s Mounjaro (tirzepatide)—have highlighted the lucrative potential offered by this market. Encouraged by the performance of these […]
Read more

Nanoscope Therapeutics MCO-010 poses looming challenge to Spark Therapeutics Luxturna in retinitis market, says GlobalData

Nanoscope Therapeutics’ gene therapy MCO-010 (sonpiretigene isteparvovec) is in the spotlight with encouraging Phase IIb results from its RESTORE trial (NCT04945772) in the retinitis pigmentosa (retinitis) market. Offering a new mechanism of action, it presents a looming challenge to Spark Therapeutics’ Luxturna (voretigene neparvovec-rzyl), the current frontrunner in gene therapy for retinitis. With promising safety […]
Read more

Basilea’s Zevtera will play unique yet critical role in MRSAB as first new therapy to gain FDA approval in over 15 years, says GlobalData

The FDA has approved Basilea Pharmaceutica’s advanced generation cephalosporin antibiotic, Zevtera (ceftobiprole medocaril), for the treatment of three major indications: Staphylococcus aureus bacteremia (SAB), including right-sided infective endocarditis, acute bacterial skin and skin structure infections (ABSSSI), and community-acquired bacterial pneumonia (CABP). As the first drug to reach the US market for the treatment of SAB in […]
Read more

Generics gain ground, yet HCPs still favor branded drugs, finds GlobalData

Generic drugs are often hailed as an effective cost-containment measure for healthcare systems that often have outdated or ineffective financing mechanisms. Despite their increasing usage, a significant proportion of healthcare professionals (HCPs) still tend to favor branded drugs, finds GlobalData’s, a leading data and analytics company. GlobalData’s survey “Generic Drugs – Physician Perspective” uncovered that […]
Read more

Pfizer’s Velsipity UK approval will raise competition in ulcerative colitis market, says GlobalData

Pfizer’s oral drug, Velsipity (etrasimod), recently received approval from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of active moderate to severe cases of ulcerative colitis (UC). With the approval, the drug will increase the competition in the UC market, where multiple players already intensively compete for their market shares, says […]
Read more

GlobalData highlights urgent need for improved osteoporosis management to enhance patient outcomes

Osteoporosis, characterized by bone mass reduction, poses challenges in early detection due to often painless fractures. As a result, addressing inconsistent drug compliance rates in osteoporosis management is imperative for enhancing patient outcomes. Experts highlight prolonged treatment regimens as a significant hurdle, necessitating comprehensive measures for patient education and adherence to improve healthcare delivery and […]
Read more

Active cooperation among APAC pharma companies gaining traction, says GlobalData

In the dynamic landscape of the pharmaceutical industry, collaboration often serves as the key to innovation and expanding market presence. In recent years, the Asia-Pacific (APAC) market has emerged as a hub for pharmaceutical development and investment, attracting attention from both local and global players. While cooperation between APAC-based pharmaceutical companies and their global counterparts […]
Read more

Pfizer’s Braftovi to command 42% share of BRAF inhibitors melanoma market by 2028, forecasts GlobalData

Since Roche‘s Zelboraf gained (vemurafenib) FDA approval in 2011, significant strides have been made in BRAF-targeted cancer therapies, underscoring the significance of combating BRAF mutations in melanoma. Against this backdrop, Pfizer‘s Braftovi (encorafenib) is positioned to secure a dominant 42% share of the BRAF inhibitors market for melanoma by 2028, underscoring its pivotal role in […]
Read more

FDA approval for Madrigal’s Rezdiffra in metabolic dysfunction-associated steatohepatitis will set precedence for approval of future pipeline agents, says GlobalData

Following the news on 14 March 2024 that FDA has granted accelerated approval for Madrigal Pharmaceuticals’ thyroid hormone receptor (THR)-β agonist Rezdiffra (resmetirom) for the treatment of patients with metabolic dysfunction-associated steatohepatitis (MASH), also known as nonalcoholic steatohepatitis (NASH), with moderate to advanced liver fibrosis; Sravani Meka MPH, Senior Pharma Analyst at GlobalData, a leading […]
Read more
1 … 22 23 24 25 26 … 110